Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

cutbacks

- PMLiVE

AZ’s Imfinzi joins immunotherapy drive in small cell lung cancer

Tecentriq the leader in setting

- PMLiVE

FDA fast-tracks Jardiance for heart failure review

Would challenge Novartis' Entresto

25 Women Leaders in UK Healthcare

Women trailblazers helping to shape the future of healthcare (Part 1)

- PMLiVE

Lynparza scores approval for first line ovarian use in Europe

Partners plan further expansion

Novartis day

Novartis close to US bribery settlement

Company faces huge damages pay out

- PMLiVE

AZ says Farxiga cuts kidney disease in type 2 diabetes

Helps in SGLT2 inhibitor battle with Jardiance

- PMLiVE

AZ reports stellar results for Lynparza in pancreatic cancer

Plans to file as soon as possible

- PMLiVE

Boehringer eyes rare disease use for respiratory blockbuster

Would help support respiratory franchise

Teva Pharma logo

US states sue generic firms over ‘inflated’ prices

Companies accused of “multi-billion dollar fraud" and conspiracy

- PMLiVE

AZ invests more in IO with Transgene oncolytic virus deal

Opportunity for combinations with IO pipeline

- PMLiVE

Brexit clock ticking once again, UK heads for European elections

New deadline gives pharma more time, but no more clarity

- PMLiVE

Lynparza could soon add first line ovarian use in Europe

Also first PARP inhibitor launched in China

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links